Andrea DiFabio Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Xenon Pharmaceuticals

Ms. DiFabio has served as our Chief Legal Officer and Corporate Secretary since November 2022. Prior to joining Xenon, Ms. DiFabio was the Chief Legal & Administrative Officer and Corporate Secretary at Repertoire Immune Medicines, Inc. from March 2020 to October 2022, where she developed broad experience supporting all aspects of the company, including business and clinical development, investor communications, risk management, and developing the company’s IP and communication strategy. From 2019 to 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc. Prior to its acquisition by Sanofi for $11.6 billion in early 2018, Ms. DiFabio served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Bioverativ Inc. from late 2016 to 2018 after playing a key role in this spinoff company of Biogen Inc. Previously, Ms. DiFabio joined Biogen in 2006 as Corporate Counsel and was promoted to Vice President, Chief US Counsel in 2007 and subsequently to various positions of increasing responsibility, where she was involved in key strategic transactions, as well as the approval and launch of numerous neurology products. Prior to her experience at Biogen, from 1999 to 2006, Ms. DiFabio was a member of the executive team and senior legal counsel at Parexel International, a publicly traded clinical research organization. Ms. DiFabio earned a Juris Doctor degree from Northeastern University School of Law, and a Bachelor of Arts, Summa Cum Laude from Boston University, where she also participated in the Executive MBA Program.

What is Andrea DiFabio's net worth?: The estimated net worth of Andrea DiFabio is at least $283.30 thousand as of March 10th, 2026. Ms. DiFabio owns 4,893 shares of Xenon Pharmaceuticals stock worth more than $283,305 as of March 12th. This net worth approximation does not reflect any other investments that Ms. DiFabio may own. Additionally, Ms. DiFabio receives an annual salary of $200,510.00 as Chief Legal Officer and Corporate Secretary at Xenon Pharmaceuticals. Learn More about Andrea DiFabio's net worth.
How old is Andrea DiFabio?: Ms. DiFabio is currently 56 years old. There are 7 older executives and no younger executives at Xenon Pharmaceuticals. The oldest executive at Xenon Pharmaceuticals is Ms. Shelley McCloskey B.A., Executive Vice President of Human Resources, who is 64 years old. Learn More on Andrea DiFabio's age.
What is Andrea DiFabio's salary?: As the Chief Legal Officer and Corporate Secretary of Xenon Pharmaceuticals Inc., Ms. DiFabio earns $200,510.00 per year. There are 6 executives that earn more than Ms. DiFabio. The highest earning executive at Xenon Pharmaceuticals is Mr. Ian C. Mortimer C.M.A., CPA, M.B.A., President, CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Andrea DiFabio's salary.
How do I contact Andrea DiFabio?: The corporate mailing address for Ms. DiFabio and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Andrea DiFabio's contact information.
Has Andrea DiFabio been buying or selling shares of Xenon Pharmaceuticals?: During the last quarter, Andrea DiFabio has sold $156,706.77 in Xenon Pharmaceuticals stock. Most recently, Andrea Difabio sold 2,607 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a transaction totalling $156,706.77. Following the completion of the sale, the insider now directly owns 4,893 shares of the company's stock, valued at $294,118.23. Learn More on Andrea DiFabio's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes Sherry Aulin (CFO), Andrea DiFabio (Chief Legal Officer and Corporate Secretary), James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 376,952 shares worth more than $21,217,970.73. The most recent insider tranaction occured on March, 10th when insider Christopher John Kenney sold 2,771 shares worth more than $166,564.81. Insiders at Xenon Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 3/10/2026.

Andrea DiFabio Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Sell	2,607	$60.11	$156,706.77	4,893

Andrea DiFabio Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $57.90

$56.92

$59.68

50 Day Range

MA: $43.49

$39.98

$62.76

2 Week Range

Now: $57.90

$26.74

$63.95

Volume

2,870,154 shs

Average Volume

1,816,125 shs

Market Capitalization

$4.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Andrea DiFabio Biography and Net Worth

What is Andrea DiFabio's net worth?

How old is Andrea DiFabio?

What is Andrea DiFabio's salary?

How do I contact Andrea DiFabio?

Has Andrea DiFabio been buying or selling shares of Xenon Pharmaceuticals?

Who are Xenon Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Xenon Pharmaceuticals?